123 related articles for article (PubMed ID: 37516394)
1. TCFL5 knockdown sensitizes DLBCL to doxorubicin treatment via regulation of GPX4.
Lu X; Zhang Q; Xie Y
Cell Signal; 2023 Oct; 110():110831. PubMed ID: 37516394
[TBL] [Abstract][Full Text] [Related]
2. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
Wang S; Sun L
Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287
[TBL] [Abstract][Full Text] [Related]
3. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
[TBL] [Abstract][Full Text] [Related]
4. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
[TBL] [Abstract][Full Text] [Related]
5. SECISBP2 is a novel prognostic predictor that regulates selenoproteins in diffuse large B-cell lymphoma.
Taguchi T; Kurata M; Onishi I; Kinowaki Y; Sato Y; Shiono S; Ishibashi S; Ikeda M; Yamamoto M; Kitagawa M; Yamamoto K
Lab Invest; 2021 Feb; 101(2):218-227. PubMed ID: 33077808
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
7. Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Qing K; Jin Z; Xu Z; Wang W; Li X; Zhang Y; Wang L; Zhu H; Xiang R; Wu S; Li R; Jiang G; Xue K; Li J
Chemotherapy; 2022; 67(1):12-23. PubMed ID: 34844236
[TBL] [Abstract][Full Text] [Related]
8. Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma.
Maxwell SA; Cherry EM; Bayless KJ
Leuk Lymphoma; 2011 May; 52(5):849-64. PubMed ID: 21323512
[TBL] [Abstract][Full Text] [Related]
9. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen.
Maxwell SA; Li Z; Jaya D; Ballard S; Ferrell J; Fu H
J Biol Chem; 2009 Aug; 284(33):22379-22389. PubMed ID: 19525224
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
11. ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.
Song YH; Zhong MZ; Gan PP; Yi PY; Tang YH; Liu YP; Jiang JQ; Li L
Tumour Biol; 2014 Dec; 35(12):11809-17. PubMed ID: 25344211
[TBL] [Abstract][Full Text] [Related]
12. Sirt1 gene confers Adriamycin resistance in DLBCL via activating the PCG-1α mitochondrial metabolic pathway.
Zhou Z; Ma D; Li P; Wang P; Liu P; Wei D; Wang J; Qin Z; Fang Q; Wang J
Aging (Albany NY); 2020 Jun; 12(12):11364-11385. PubMed ID: 32570218
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.
Bai H; Wei J; Deng C; Yang X; Wang C; Xu R
Int J Hematol; 2013 Feb; 97(2):223-31. PubMed ID: 23275230
[TBL] [Abstract][Full Text] [Related]
14. CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a/b to disinhibit PD-L1.
Dong L; Huang J; Gao X; Du J; Wang Y; Zhao L
Cancer Sci; 2022 Aug; 113(8):2888-2903. PubMed ID: 35579082
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.
Due H; Schönherz AA; Ryø L; Primo MN; Jespersen DS; Thomsen EA; Roug AS; Xiao M; Tan X; Pang Y; Young KH; Bøgsted M; Mikkelsen JG; Dybkær K
Blood Adv; 2019 Apr; 3(7):1185-1196. PubMed ID: 30967394
[TBL] [Abstract][Full Text] [Related]
16. PRDX6 promotes proliferation and induces chemo-resistance via peroxidase activity in Toledo diffuse large B-cell lymphoma cells.
Fang Z; Liu T; Liu X; Lu Y; Sun Y; Xiao R; Fan R; Liu L
Transl Cancer Res; 2019 Sep; 8(5):1772-1781. PubMed ID: 35116928
[TBL] [Abstract][Full Text] [Related]
17. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.
Deng SH; Wu DM; Li L; Liu T; Zhang T; Li J; Yu Y; He M; Zhao YY; Han R; Xu Y
Biochem Biophys Res Commun; 2021 Apr; 549():54-60. PubMed ID: 33662669
[TBL] [Abstract][Full Text] [Related]
18. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
19. Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods.
Liu Y; Zeng L; Zhang S; Zeng S; Huang J; Tang Y; Zhong M
Med Oncol; 2013 Jun; 30(2):528. PubMed ID: 23504336
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
Ageberg M; Rydström K; Lindén O; Linderoth J; Jerkeman M; Drott K
Exp Cell Res; 2011 May; 317(8):1179-91. PubMed ID: 21324313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]